Sandoz Takes Zero-Profit Approach To COVID-19 In Africa
As mAbxience Partners With AstraZeneca To Produce Oxford Vaccine
Executive Summary
As Sandoz tries to assist African Union member states by selling its pandemic response portfolio medicines for zero profit, mAbxience has partnered with AstraZeneca to produce a vaccine. And CDMO Hovione has struck a deal with Ligand to boost manufacturing of Captisol, a critical ingredient for Gilead’s remdesivir.
You may also be interested in...
Indoco Counts On Indian Market Bouncing Back
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
After Glenmark, Dr Reddy’s Launches Favipiravir For Indian Market
While Dr Reddy’s partners with Fujifilm Toyama for favipiravir for the Indian market, Pfizer and Gilead join together to increase the manufacturing and supply of investigational antiviral treatment remdesivir. Mylan donates a million dollars to Sesame Workshop to provide socio-emotional support to children and families to cope with the uncertainties caused by COVID-19, while Glenmark introduces a higher strength of Fabiflu for the Indian market.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.